Aislinn Antrim, Associate Editorial Director

Prevention of acute cardiac events may be another consideration for future postlicensure studies of RSV vaccines.

Tisotumab vedotin-tftv is the first antibody-drug conjugate to demonstrate positive overall survival data in patients with previously treated recurrent or metastatic cancer.

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.

The finding did not reach statistical significance in the primary composite endpoint.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.

In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.

Identifying the best uses for these tools, whether in patient education, data collection, improving efficiencies, or other uses, could significantly improve the future of pharmacy.

Integrate nutrition into the health care system with a proactive approach to chronic disease management

The application was previously granted fast track designation and orphan drug designation.

Investing in community relationships and health literacy are key steps pharmacists can take to improve equity.

pCR rates improve regardless of whether patients received full chemotherapy doses.

Trastuzumab deruxtecan and elacestrant represent important new treatment options.

The combination resulted in numerically longer OS compared with an NSAI alone.

Almost 80% of patients have now stopped treatment with ribociclib, but benefit persists and is greater than it was 6 months ago, according to the presenter.

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

Improvements in PFS were also seen among patients with brain metastases.

pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Biologic rationale, biomarker precision, and efficacy results in the biomarker-negative population all helped FDA officials decide the final indication.

Evidence has shown that reversing pro-cancer effects requires significant weight loss as well as substantial metabolic reprogramming.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

The designation allows expedited development of ADP101 as a treatment for food allergy in children ages 4 to 17 with confirmed allergy to 1 or more of the 15 foods in the drug product.

Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.

The approval marks the first new biologic treatment option for this patient population in nearly a decade.

Risk of long COVID was 3 times higher in those who had pre-existing conditions and a short sleep duration, compared to those with no pre-existing conditions and adequate sleep.

The approval marks the first and only once-daily target therapy for generalized myasthenia gravis for self-administration in this patient population.

If health care professionals want to increase access and care in these underrepresented communities, an important first step is also increasing the representation of those groups in health care itself.